Do you find our website to be helpful?
Yes   No

NEW FRONTIERS IN ANTIDEPRESSANT TREATMENT

In the past two years many of my patiens have been very curious about the FDA approval of some novel antidepressants,  Fetzima,  Trintellix, and Viibryd -- all of which have similar mechanisms of action to existing antidepressant.   So in considering their novelty - there isn't anything significantly new or different about what these medications are doing.   What is different - is that they present new possibilities for patients who have found it hard to tolerate earlier medications.  It's not that they're better -- it's more that they represent more options that can work with a wider range of genetic subtypes.  Selective serotonin reuptake inhibitors (Trinellix and Viibryd) and combined selective serotonin reuptake inhibitos (Fetzima) all have similar mechanisms of action -- but have very different structures.  Because of the different structures - they can interact quite differently with the overall functioning of the body.   So there is a wider range of possiblity here to expereince signifcantly fewer side effects -- particularly weight gain or sexual dysfunction -- and so they might be worth a try.   It's like adding a slight change of color to a flower.  It might not be noticeable to some, but to toehrs it can make a world of difference!

Author
David Salvage, MD, FAPM

You Might Also Enjoy...